CAMBRIDGE, Mass., Oct. 8, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will webcast presentations from its Research and Development (R&D) Day on Friday, October 16, 2015 starting at 9:00 a.m. ET in New York City.
Presentations will include a review of Agios' research approach and clinical development strategy for the company's lead cancer metabolism and rare genetic metabolic disorders programs. Along with the Agios team, external speakers will review the reported clinical data from these programs and the diseases that these investigational medicines aim to treat, including acute myeloid leukemia, advanced solid tumors and pyruvate kinase deficiency.
Agios speakers scheduled to present include:
David Schenkein, M.D., Chief Executive Officer
Scott Biller, Ph.D., Chief Scientific Officer
Chris Bowden, M.D., Chief Medical Officer
Sam Agresta, M.D., Vice President, Head of Clinical Development
Ann Barbier, M.D., Ph.D., Vice President, Clinical Development, Rare Genetic Diseases
Timothy Cloughesy, M.D., Director, UCLA Neuro-Oncology Program and Professor, Ronald Reagan UCLA Medical Center
Courtney DiNardo, M.D., MSCE, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center
Agios invites the public and media to listen to the presentations via a live webcast that can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at agios.com. The presentations are scheduled to begin at approximately 9:00 a.m. ET. A replay of the webcast will be archived on the Agios website for approximately 30 days following the presentation.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of Agios' product candidates targeting IDH1/IDH2 or pyruvate kinase-R mutations, including AG-221, AG-120, AG-881 and AG-348; and the benefit of its strategic plans and focus. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "potential," "hope," "could," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations, such as its agreements with Celgene; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, and other filings that Agios may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Renee Leck, Senior Manager,
Investor Relations and Public Relations